RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that Vipin K. Garg, Ph.D., President and CEO, and Richard I. Eisenstadt, Vice President and CFO, will present at the following upcoming investor conferences:
-
Citi 2012 Global Health Care Conference taking place at The Waldorf Astoria, New York, NY February 27-29, 2012. Tranzyme's presentation is scheduled for Monday, February 27th at 4:30 pm ET in the Jade Room, followed by a breakout session in the Louis VXI Suite West.
- Cowen and Company 32nd Annual Health Care Conference taking place at The Boston Marriott Copley Place, Boston, MA March 5-7, 2012. Tranzyme's presentation is scheduled for Monday, March 5th at 3:30 pm ET.
A live audio webcast of the presentations will be available in the "Investors" section of the Tranzyme Pharma website, www.tranzyme.com, following each conference.
About Tranzyme Pharma
Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 20 percent of adults worldwide are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing an intravenous drug, ulimorelin, for patients in acute (hospital-based) settings, as well as an oral drug, TZP-102, for chronic conditions. Top-line data from the recently completed Phase 3 trials of ulimorelin are expected in the first half of 2012, and enrollment in a Phase 2b trial of TZP-102 is ongoing. Together these product candidates target a significant underserved market. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.